Diuretics are Similar to Losartan on Echocardiographic Target-Organ Damage in Stage I Hypertension. PREVER-Treatment Study.
Carolina BertoluciMurilo FoppaAngela Barreto Santiago SantosSandra C FuchsFlávio Danni FuchsPublished in: Arquivos brasileiros de cardiologia (2019)
Blood pressure (BP)-lowering therapy improves left ventricular (LV) parameters of hypertensive target-organ damage in stage II hypertension, but whether there is a drug-class difference in echocardiographic parameters in stage I hypertension patients is less often studied. In the PREVER treatment study, where individuals with stage I hypertension were randomized for treatment with diuretics (chlorthalidone/amiloride) or losartan, 110 participants accepted to participate in a sub-study, where two-dimensional echocardiograms were performed at baseline and after 18 months of antihypertensive treatment. As in the general study, systolic BP reduction was similar with diuretics or with losartan. Echocardiographic parameters showed small but significant changes in both treatment groups, with a favorable LV remodeling with antihypertensive treatment for 18 months when target blood pressure was achieved either with chlorthalidone/amiloride or with losartan as the initial treatment strategy. In conclusion, even in stage I hypertension, blood pressure reduction is associated with improvement in echocardiographic parameters, either with diuretics or losartan as first-drug regimens.
Keyphrases
- blood pressure
- left ventricular
- hypertensive patients
- ejection fraction
- heart rate
- end stage renal disease
- emergency department
- chronic kidney disease
- stem cells
- clinical trial
- bone marrow
- acute myocardial infarction
- skeletal muscle
- mitral valve
- left atrial
- metabolic syndrome
- mesenchymal stem cells
- atrial fibrillation
- blood glucose
- percutaneous coronary intervention
- prognostic factors
- study protocol
- peritoneal dialysis